Department of Psychiatry and Behavioral Sciences (A.S., J.C.), Boston Children's Hospital, MA.
Department of Psychiatry (A.S., J.C.), Harvard Medical School, Boston, MA.
Circulation. 2022 Apr 12;145(15):1108-1119. doi: 10.1161/CIRCULATIONAHA.121.056305. Epub 2022 Feb 10.
Neurodevelopmental impairment is common in children with congenital heart disease (CHD), but postnatal variables explain only 30% of the variance in outcomes. To explore whether the antecedents for neurodevelopmental disabilities might begin in utero, we analyzed whether fetal brain volume predicted subsequent neurodevelopmental outcome in children with CHD.
Fetuses with isolated CHD and sociodemographically comparable healthy control fetuses underwent fetal brain magnetic resonance imaging and 2-year neurodevelopmental evaluation with the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) and the Adaptive Behavior Assessment System, Third Edition (ABAS-3). Hierarchical regression evaluated potential predictors of Bayley-III and ABAS-3 outcomes in the CHD group, including fetal total brain volume adjusted for gestational age and sex, sociodemographic characteristics, birth measures, and medical history.
The CHD group (n=52) had lower Bayley-III cognitive, language, and motor scores than the control group (n=26), but fetal brain volumes were similar. Within the CHD group, larger fetal total brain volume correlated with higher Bayley-III cognitive, language, and motor scores and ABAS-3 adaptive functioning scores (=0.32-0.47; all <0.05), but this was not noted in the control group. Fetal brain volume predicted 10% to 21% of the variance in neurodevelopmental outcome measures in univariate analyses. Multivariable models that also included social class and postnatal factors explained 18% to 45% of the variance in outcome, depending on developmental domain. Moreover, in final multivariable models, fetal brain volume was the most consistent predictor of neurodevelopmental outcome across domains.
Small fetal brain volume is a strong independent predictor of 2-year neurodevelopmental outcomes and may be an important imaging biomarker of future neurodevelopmental risk in CHD. Future studies are needed to support this hypothesis. Our findings support inclusion of fetal brain volume in risk stratification models and as a possible outcome in fetal neuroprotective intervention studies.
神经发育障碍在患有先天性心脏病 (CHD) 的儿童中很常见,但产后变量仅能解释结果的 30%。为了探索神经发育障碍的潜在原因是否可能始于宫内,我们分析了胎儿脑容量是否可以预测患有 CHD 的儿童随后的神经发育结果。
患有孤立性 CHD 的胎儿和社会人口统计学上可比的健康对照组胎儿接受了胎儿脑磁共振成像和 2 年神经发育评估,使用贝利婴幼儿发展量表第三版(Bayley-III)和适应行为评估系统第三版(ABAS-3)。分层回归评估了 CHD 组中 Bayley-III 和 ABAS-3 结果的潜在预测因素,包括调整胎龄和性别、社会人口统计学特征、出生指标和病史后的胎儿总脑容量。
CHD 组(n=52)的 Bayley-III 认知、语言和运动评分低于对照组(n=26),但胎儿脑容量相似。在 CHD 组中,较大的胎儿总脑容量与较高的 Bayley-III 认知、语言和运动评分和 ABAS-3 适应功能评分相关(=0.32-0.47;均<0.05),但在对照组中未观察到这一点。在单变量分析中,胎儿脑容量可预测神经发育结果测量的 10%至 21%的变异性。多变量模型,其中还包括社会阶层和产后因素,取决于发育领域,可解释结果的 18%至 45%的变异性。此外,在最终的多变量模型中,胎儿脑容量是跨领域神经发育结果的最一致预测因素。
胎儿脑容量小是 2 岁神经发育结果的强有力独立预测因素,可能是 CHD 未来神经发育风险的重要影像学生物标志物。需要进一步的研究来支持这一假设。我们的研究结果支持将胎儿脑容量纳入风险分层模型,并作为胎儿神经保护干预研究的潜在结果。